Intellia Therapeutics (NTLA) to Release Quarterly Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect Intellia Therapeutics to post earnings of ($1.26) per share and revenue of $11.39 million for the quarter.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA traded down $0.55 during midday trading on Tuesday, reaching $7.89. 722,192 shares of the stock were exchanged, compared to its average volume of 2,416,770. The stock has a market capitalization of $817.06 million, a P/E ratio of -1.45 and a beta of 2.33. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.18. The company has a 50 day simple moving average of $8.30 and a 200 day simple moving average of $11.29.

Analysts Set New Price Targets

Several research firms have recently issued reports on NTLA. Oppenheimer lowered their price objective on Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating for the company in a research report on Monday, January 13th. Wells Fargo & Company lowered their price objective on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Wedbush reiterated a "neutral" rating and issued a $10.00 price objective (down from $14.00) on shares of Intellia Therapeutics in a research report on Friday, January 10th. Morgan Stanley lowered Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their price target for the stock from $56.00 to $11.00 in a research note on Monday, January 27th. Finally, Wolfe Research raised Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price target on the stock in a research note on Monday, April 21st. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $36.68.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.